{"id":62941,"date":"2026-04-12T22:25:20","date_gmt":"2026-04-12T14:25:20","guid":{"rendered":"https:\/\/flcube.com\/?p=62941"},"modified":"2026-04-12T22:25:21","modified_gmt":"2026-04-12T14:25:21","slug":"oricell-therapeutics-raises-110m-in-pre-ipo-round-accelerates-global-expansion-of-first-in-class-car-t-for-liver-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=62941","title":{"rendered":"Oricell Therapeutics Raises $110M+ in Pre\u2011IPO Round \u2013 Accelerates Global Expansion of First\u2011in\u2011Class CAR\u2011T for Liver Cancer"},"content":{"rendered":"\n<p><strong>Oricell Therapeutics Co., Ltd.<\/strong> announced completion of a <strong>US$110\u202fmillion+ pre\u2011IPO financing round<\/strong>, positioning the cell therapy innovator for <strong>capital market entry<\/strong> and accelerated global clinical development. The round was <strong>co\u2011led by Vivo Capital, Beijing Medical and Health Care Industry Investment Fund, Qiming Venture Partners, and a leading global healthcare fund<\/strong>, with participation from an <strong>international sovereign wealth fund, E\u2011Town Capital, Luxin Venture Capital, NGS Super, Elikon Investment, and Talon Capital<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financing-overview\">Financing Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Amount Raised<\/strong><\/td><td>&gt;US$110\u202fmillion<\/td><\/tr><tr><td><strong>Round<\/strong><\/td><td>Pre\u2011IPO financing<\/td><\/tr><tr><td><strong>Co\u2011Leads<\/strong><\/td><td>Vivo Capital, Beijing Medical and Health Care Industry Investment Fund, Qiming Venture Partners, leading global healthcare fund<\/td><\/tr><tr><td><strong>Participants<\/strong><\/td><td>International sovereign wealth fund, E\u2011Town Capital, Luxin Venture Capital, NGS Super, Elikon Investment, Talon Capital<\/td><\/tr><tr><td><strong>Use of Proceeds<\/strong><\/td><td>Global expansion, clinical development, technology platform strengthening, capital market preparation<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-lead-product-ori-c101\">Lead Product: Ori\u2011C101<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Attribute<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>Ori\u2011C101<\/td><\/tr><tr><td><strong>Modality<\/strong><\/td><td><strong>Autologous CAR\u2011T therapy<\/strong><\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td><strong>GPC3<\/strong> (glypican\u20113)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td><strong>Advanced hepatocellular carcinoma (HCC)<\/strong><\/td><\/tr><tr><td><strong>Status<\/strong><\/td><td>IIT (investigator\u2011initiated trials) completed; <strong>pivotal trials on track<\/strong><\/td><\/tr><tr><td><strong>Differentiation<\/strong><\/td><td><strong>Potential to become first approved CAR\u2011T therapy for HCC worldwide<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-amp-strategic-positioning\">Clinical &amp; Strategic Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Unmet Need:<\/strong> HCC is the <strong>6th most common cancer globally<\/strong> with <strong>~900,000 annual new cases<\/strong>; 5\u2011year survival &lt;20% for advanced disease; <strong>no approved CAR\u2011T therapies<\/strong> for solid tumors<\/li>\n\n\n\n<li><strong>Clinical Validation:<\/strong> Positive IIT data supports <strong>registrational trial initiation<\/strong>; potential <strong>BLA submission 2027\u20112028<\/strong> in China with <strong>US\/EU pathways<\/strong> to follow<\/li>\n\n\n\n<li><strong>First\u2011Mover Advantage:<\/strong> GPC3\u2011targeted CAR\u2011T addresses <strong>>70% of HCC cases<\/strong> expressing target; category leadership in solid tumor cell therapy<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-platform-amp-pipeline\">Technology Platform &amp; Pipeline<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Platform Capability<\/th><th>Application<\/th><\/tr><\/thead><tbody><tr><td><strong>Secreted CAR\u2011T<\/strong><\/td><td>Enhanced tumor penetration and persistence<\/td><\/tr><tr><td><strong>Rapid\u2011manufacturing<\/strong><\/td><td>Reduced vein\u2011to\u2011vein time improving patient access<\/td><\/tr><tr><td><strong>In vivo CAR\u2011T<\/strong><\/td><td>Eliminating ex vivo manufacturing complexity<\/td><\/tr><tr><td><strong>Multi\u2011target, multi\u2011mechanism<\/strong><\/td><td>Addressing tumor heterogeneity and resistance<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pipeline Depth:<\/strong> Continuous incubation of <strong>next\u2011generation CAR\u2011T products<\/strong> targeting diverse solid tumor indications beyond HCC<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-outlook\">Market Context &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Solid Tumor CAR\u2011T Market:<\/strong> <strong>US$15\u201120\u202fbillion<\/strong> addressable opportunity; current approved therapies limited to hematologic malignancies<\/li>\n\n\n\n<li><strong>HCC Therapeutic Landscape:<\/strong> Dominated by <strong>TKIs (sorafenib, lenvatinib)<\/strong> and <strong>IO combinations<\/strong>; CAR\u2011T offers <strong>potential curative mechanism<\/strong> for refractory patients<\/li>\n\n\n\n<li><strong>Revenue Potential:<\/strong> Peak Ori\u2011C101 sales projected at <strong>US$500\u202fmillion\u20111\u202fbillion<\/strong> globally by 2033, assuming first\u2011to\u2011market position and 15\u201125% penetration in 3L+ HCC<\/li>\n\n\n\n<li><strong>IPO Trajectory:<\/strong> Pre\u2011IPO round structure suggests <strong>Hong Kong or US listing<\/strong> targeted <strong>2026\u20112027<\/strong>; valuation expected to exceed <strong>US$500\u202fmillion<\/strong> at IPO<\/li>\n\n\n\n<li><strong>Platform Value:<\/strong> Full\u2011spectrum CAR\u2011T technology system supports <strong>multiple partnership opportunities<\/strong> and <strong>pipeline expansion<\/strong> into gastric, lung, and ovarian cancers<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical trial outcomes, regulatory pathways, financing deployment, and capital market timing for Oricell Therapeutics. Actual results may differ due to risks including solid tumor CAR\u2011T efficacy challenges, manufacturing scalability, competitive advances, and IPO market conditions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Oricell Therapeutics Co., Ltd. announced completion of a US$110\u202fmillion+ pre\u2011IPO financing round, positioning the cell&#8230;<\/p>\n","protected":false},"author":1,"featured_media":62942,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[21,77,113],"class_list":["post-62941","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-car-t","tag-cell-therapy","tag-oricell-therapeutics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Oricell Therapeutics Raises $110M+ in Pre\u2011IPO Round \u2013 Accelerates Global Expansion of First\u2011in\u2011Class CAR\u2011T for Liver Cancer - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Oricell Therapeutics Co., Ltd. announced completion of a US$110\u202fmillion+ pre\u2011IPO financing round, positioning the cell therapy innovator for capital market entry and accelerated global clinical development. The round was co\u2011led by Vivo Capital, Beijing Medical and Health Care Industry Investment Fund, Qiming Venture Partners, and a leading global healthcare fund, with participation from an international sovereign wealth fund, E\u2011Town Capital, Luxin Venture Capital, NGS Super, Elikon Investment, and Talon Capital.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=62941\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Oricell Therapeutics Raises $110M+ in Pre\u2011IPO Round \u2013 Accelerates Global Expansion of First\u2011in\u2011Class CAR\u2011T for Liver Cancer\" \/>\n<meta property=\"og:description\" content=\"Oricell Therapeutics Co., Ltd. announced completion of a US$110\u202fmillion+ pre\u2011IPO financing round, positioning the cell therapy innovator for capital market entry and accelerated global clinical development. The round was co\u2011led by Vivo Capital, Beijing Medical and Health Care Industry Investment Fund, Qiming Venture Partners, and a leading global healthcare fund, with participation from an international sovereign wealth fund, E\u2011Town Capital, Luxin Venture Capital, NGS Super, Elikon Investment, and Talon Capital.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=62941\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-12T14:25:20+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-12T14:25:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1204.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62941#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62941\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Oricell Therapeutics Raises $110M+ in Pre\u2011IPO Round \u2013 Accelerates Global Expansion of First\u2011in\u2011Class CAR\u2011T for Liver Cancer\",\"datePublished\":\"2026-04-12T14:25:20+00:00\",\"dateModified\":\"2026-04-12T14:25:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62941\"},\"wordCount\":487,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62941#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1204.webp\",\"keywords\":[\"CAR-T\",\"Cell-therapy\",\"Oricell Therapeutics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62941#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62941\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=62941\",\"name\":\"Oricell Therapeutics Raises $110M+ in Pre\u2011IPO Round \u2013 Accelerates Global Expansion of First\u2011in\u2011Class CAR\u2011T for Liver Cancer - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62941#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62941#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1204.webp\",\"datePublished\":\"2026-04-12T14:25:20+00:00\",\"dateModified\":\"2026-04-12T14:25:21+00:00\",\"description\":\"Oricell Therapeutics Co., Ltd. announced completion of a US$110\u202fmillion+ pre\u2011IPO financing round, positioning the cell therapy innovator for capital market entry and accelerated global clinical development. The round was co\u2011led by Vivo Capital, Beijing Medical and Health Care Industry Investment Fund, Qiming Venture Partners, and a leading global healthcare fund, with participation from an international sovereign wealth fund, E\u2011Town Capital, Luxin Venture Capital, NGS Super, Elikon Investment, and Talon Capital.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62941#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62941\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62941#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1204.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1204.webp\",\"width\":1080,\"height\":608,\"caption\":\"Oricell Therapeutics Raises $110M+ in Pre\u2011IPO Round \u2013 Accelerates Global Expansion of First\u2011in\u2011Class CAR\u2011T for Liver Cancer\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62941#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Oricell Therapeutics Raises $110M+ in Pre\u2011IPO Round \u2013 Accelerates Global Expansion of First\u2011in\u2011Class CAR\u2011T for Liver Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Oricell Therapeutics Raises $110M+ in Pre\u2011IPO Round \u2013 Accelerates Global Expansion of First\u2011in\u2011Class CAR\u2011T for Liver Cancer - Insight, China&#039;s Pharmaceutical Industry","description":"Oricell Therapeutics Co., Ltd. announced completion of a US$110\u202fmillion+ pre\u2011IPO financing round, positioning the cell therapy innovator for capital market entry and accelerated global clinical development. The round was co\u2011led by Vivo Capital, Beijing Medical and Health Care Industry Investment Fund, Qiming Venture Partners, and a leading global healthcare fund, with participation from an international sovereign wealth fund, E\u2011Town Capital, Luxin Venture Capital, NGS Super, Elikon Investment, and Talon Capital.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=62941","og_locale":"en_US","og_type":"article","og_title":"Oricell Therapeutics Raises $110M+ in Pre\u2011IPO Round \u2013 Accelerates Global Expansion of First\u2011in\u2011Class CAR\u2011T for Liver Cancer","og_description":"Oricell Therapeutics Co., Ltd. announced completion of a US$110\u202fmillion+ pre\u2011IPO financing round, positioning the cell therapy innovator for capital market entry and accelerated global clinical development. The round was co\u2011led by Vivo Capital, Beijing Medical and Health Care Industry Investment Fund, Qiming Venture Partners, and a leading global healthcare fund, with participation from an international sovereign wealth fund, E\u2011Town Capital, Luxin Venture Capital, NGS Super, Elikon Investment, and Talon Capital.","og_url":"https:\/\/flcube.com\/?p=62941","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-12T14:25:20+00:00","article_modified_time":"2026-04-12T14:25:21+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1204.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=62941#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=62941"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Oricell Therapeutics Raises $110M+ in Pre\u2011IPO Round \u2013 Accelerates Global Expansion of First\u2011in\u2011Class CAR\u2011T for Liver Cancer","datePublished":"2026-04-12T14:25:20+00:00","dateModified":"2026-04-12T14:25:21+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=62941"},"wordCount":487,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=62941#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1204.webp","keywords":["CAR-T","Cell-therapy","Oricell Therapeutics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=62941#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=62941","url":"https:\/\/flcube.com\/?p=62941","name":"Oricell Therapeutics Raises $110M+ in Pre\u2011IPO Round \u2013 Accelerates Global Expansion of First\u2011in\u2011Class CAR\u2011T for Liver Cancer - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=62941#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=62941#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1204.webp","datePublished":"2026-04-12T14:25:20+00:00","dateModified":"2026-04-12T14:25:21+00:00","description":"Oricell Therapeutics Co., Ltd. announced completion of a US$110\u202fmillion+ pre\u2011IPO financing round, positioning the cell therapy innovator for capital market entry and accelerated global clinical development. The round was co\u2011led by Vivo Capital, Beijing Medical and Health Care Industry Investment Fund, Qiming Venture Partners, and a leading global healthcare fund, with participation from an international sovereign wealth fund, E\u2011Town Capital, Luxin Venture Capital, NGS Super, Elikon Investment, and Talon Capital.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=62941#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=62941"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=62941#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1204.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1204.webp","width":1080,"height":608,"caption":"Oricell Therapeutics Raises $110M+ in Pre\u2011IPO Round \u2013 Accelerates Global Expansion of First\u2011in\u2011Class CAR\u2011T for Liver Cancer"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=62941#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Oricell Therapeutics Raises $110M+ in Pre\u2011IPO Round \u2013 Accelerates Global Expansion of First\u2011in\u2011Class CAR\u2011T for Liver Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1204.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62941","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=62941"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62941\/revisions"}],"predecessor-version":[{"id":62943,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62941\/revisions\/62943"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/62942"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=62941"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=62941"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=62941"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}